August 19, 2025

A September Skip, The Bullish Case for Viking Therapeutics, and Lassoing the Laggards 8/19/25

Why the Fed could skip a September cut altogether, despite higher inflation data. BTIG makes the case for sticking with Viking Therapeutics despite disappointing weight loss drug trial data. Plus, the laggards our traders says to buy now.

Also available on Apple Podcasts ↗